Interferon-stimulated genes are associated with peginterferon/ribavirin treatment response regardless of IL28B alleles in hepatitis C virus/HIV-coinfected patients

AIDS

Volumn 27, Issue 5, 2013, Pages 687-696

  Rallon, Norma I ^a   Lopez Fernandez, Luis A ^b   Garcia, Maria Isabel ^b   Benguria, Alberto ^c   Fiorante, Silvana ^d   Soriano, Vincent ^a   Benito, José M ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^d UNIVERSIDAD EUROPEA DE MADRID   (Spain)

Author keywords

HIV hepatitis c virus coinfection; IL28B; Interferon; Interferonstimulated genes

Indexed keywords

DENDRITIC CELL LYSOSOME ASSOCIATED MEMBRANE PROTEIN; INTERFERON BETA SERINE; INTERLEUKIN 28B; INTERLEUKIN 6; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL4; PEGINTERFERON; RIBAVIRIN; TETRATRICOPEPTIDE REPEAT PROTEIN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; EXON; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPETENT CELL; LIVER FIBROSIS; MALE; MICROARRAY ANALYSIS; MIXED INFECTION; OPEN READING FRAME; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TETRATRICOPEPTIDE REPEAT; TREATMENT RESPONSE; VIREMIA; VIRUS LOAD;

ADULT; ALLELES; ANTIVIRAL AGENTS; COHORT STUDIES; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION REGULATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; SPAIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84876409733     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32835ce2c1     Document Type: Article

References (44)

1. Lauer G, Walker B. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
2. Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-1089.
3. Ghany M, Strader D, Thomas D, Seeff L, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
4. Ge D, Fellay J, Thompson A, Simon J, Shianna K, Urban T, et al. Genetic variation in IL28B predicts hepatitis C treatmentinduced viral clearance. Nature 2009; 461:399-401.
5. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
6. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
7. Rallón NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010; 24:F23-F29.
8. Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho A, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010; 51:788- 795.
9. Natterman J, Vogel M, Nischalke H, Danta M, Mauss S, Stellbrink H, et al. Genetic variation in IL28B and treatmentinduced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C. J Infect Dis 2011; 203:595- 601.
10. Robek M, Boyd B, Chisari F. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79:3851- 3854.
11. Kotenko S, Gallager G, Baurin V, Lewis-Antes A, Shen M, Shah N, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4:69-77.
12. Marcello T, Grakoui A, Barba-Spaeth G, Machlin E, Kotenko S, MacDonald M, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-1898.
13. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010; 139:499-509.
14. Urban T, Thompson A, Bradrick S, Fellay J, Schuppan D, Cronin K, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010; 52:1888-1896.
15. Dill M, Duong F, Vogt J, Bibert S, Bochud P, Terracciano L, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011; 140:1021-1031.
16. Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, Nischalke H, et al. Interferon-lambda serum levels in hepatitis C. J Hepatol 2011; 54:859-865.
17. Rallón NI, Soriano V, Naggie S, Restrepo C, McHutchison J, Vispo E, et al. Impact of IL28B gene polymorphisms on interferon-( 3 plasma levels during pegylated interferon-(/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV. J Antimicrob Chemother 2012; 67:1246-1249.
18. Thomas E, Gonzalez V, Li Q, Modi A, Chen W, Noureddin M, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 2012; 142:978-988.
19. Cheng M, Si Y, Yang Y, Liu X, Gong Q, Zhao J, et al. Recombinant human interleukin 28B: anti-HCV potency, receptor usage and restricted cell-type responsiveness. J Antimicrob Chemother 2012; 67:1080-1087.
20. Marukian S, Andrus L, Sheahan T, Jones C, Charles E, Ploss A, et al. Hepatitis C virus induces interferon-(and interferonstimulated genes in primary liver cultures. Hepatology 2011; 54:1913-1923.
21. Chen L, Borozan J, Feld J, Sun J, Tannis L, Coltescu C, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128:1437-1444.
22. Asselah T, Bieche I, Narguet S, Sabbagh A, Laurendeau I, Ripault M, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut 2008; 57:516-524.
23. Sarasin-Filipowicz M, Oakeley E, Duong F, Christen V, Terracciano L, Filipowicz W, et al. Interferon signalling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 2008; 105:7034-7039.
24. Abe H, Hayes CN, Ochi H, Tsuge M, Miki D, Hiraga N, et al. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J Med Virol 2011; 83:1597-1607.
25. Abe H, Hayes C, Ochi H, Maekawa T, Tsuge M, Miki D, et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol 2011; 54:1094-1101.
26. McGilvray I, Feld JJ, Chen L, Pattullo V, Guindi M, Fischer S, et al. Hepatic cell-type specific gene expression better predicts HCV treatment outcome than IL28B genotype. Gastroenterology 2012; 142:1122-1131.
27. Naggie S, Osinusi A, Katsounas A, Lempicki R, Herrmann E, Thompson AJ, et al. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology 2012; 56:444-454.
28. Berg R, Melchjorsen J, Rintahaka J, Diget E, Søby S, Horan K, et al. Genomic HIV RNA induces innate immune responses through RIG-I-dependent sensing of secondary-structured RNA. PLoS One 2012; 7:e29291.
29. Medrano J, Resino S, Vispo E, Madejón A, Labarga P, Tuma P, et al. Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV-HCV coinfected patients. J Viral Hepat 2011; 18:325-330.
30. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One 2009; 4:e8209.
31. Berenguer J, von Wichmann MA, Quereda C, Miralles P, Mallolas J, López-Aldeguer J, et al. Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIVand hepatitis C virus. J Antimicrob Chemother 2011; 66:2843-2849.
32. Pappas D, Coppola G, Gabatto P, Gao F, Geschwind D, Oksenberg J, et al. Longitudinal system-based analysis of transcriptional responses to type I interferons. Physiol Genomics 2009; 38:362-371.
33. Goertsches R, Hecker M, Koczan D, Serrano-Fernandez P, Moeller S, Thiesen H, et al. Long-term genome-wide blood RNA expression profiles yield novel molecular response candidates for IFN-beta-1b treatment in relapsing remitting MS. Pharmacogenomics 2010; 11:147-161.
34. Medrano J, Neukam K, Rallón N, Rivero A, Resino S, Naggie S, et al. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 2010; 51:1209-1216.
35. Sandler N, Koch C, Roque A, Eccleston J, Siegel R, Demino M, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011; 141:1220-1230.
36. Schroder W, Le T, Major L, Street S, Gardner J, Lambley E, et al. A physiological function of inflammation-associated SerpinB2 is regulation of adaptive immunity. J Immunol 2010; 184:2663- 2670.
37. Sugiyama S, Nakabayashi K, Baba I, Sasazuki T, Shirasawa S. Role of epiregulin in peptidoglycan-induced pro-inflammatory cytokine production by antigen presenting cells. Biochem Biophys Res Commun 2005; 337:271-274.
38. Lin Q, Fang D, Hou X, Le Y, Fang J. HCV peptide (C5A), an amphipathic (-helical peptide of hepatitis virus, is an activator of N-formyl peptide receptor in human phagocytes. J Immunol 2010; 186:2087-2094.
39. González-Cortés C, Díez-Tascón C, Guerra-Laso JM, González- Cocaño M, Rivero-Lezcano O. Nonchemotactic influence of CXCL7 on human phagocytes. Modulation of antimicrobial activity against L. pneumophila. Immunobiology 2012; 217: 394-401.
40. Morlier A, Van Damme J, Proost P. Regulation of chemokine activity by posttranslational modification. Pharmacol Ther 2008; 120:197-217.
41. Taylor MW, Tsukahara T, Brodsky L, Schaley J, Sanda C, Stephens MJ, et al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 2007; 81:3391-3401.
42. Taylor M, Tsukahara T, McClintick J, Edenberg H, Kwo P. Cyclic changes in gene expression induced by peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment. J Transl Med 2008; 6:66.
43. He X, Ji X, Hale M, Cheung R, Ahmed A, Guo Y, et al. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 2006; 44:352-359.
44. Ji X, Cheung R, Cooper S, Li Q, Greenberg H, He X. Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology 2003; 37:610- 621.